Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HIMS NASDAQ:RXRX NASDAQ:SDGR NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$32.89-2.3%$30.14$13.74▼$70.43$7.80B2.3513.17 million shs9.88 million shsRXRXRecursion Pharmaceuticals$2.94-2.6%$3.32$2.77▼$7.18$1.60B122.82 million shs19.27 million shsSDGRSchrodinger$15.32-1.8%$14.88$10.94▼$23.75$1.15B1.621.28 million shs940,293 shsSMMTSummit Therapeutics$13.81+0.4%$15.43$12.55▼$30.98$10.68B-1.263.93 million shs2.84 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health-2.20%-4.53%+2.88%+14.45%-36.45%RXRXRecursion Pharmaceuticals-2.65%-17.42%-5.47%-22.22%-45.45%SDGRSchrodinger-1.79%-7.10%-1.35%+24.15%-27.91%SMMTSummit Therapeutics+0.36%-9.44%-1.85%-45.09%-51.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$32.89-2.3%$30.14$13.74▼$70.43$7.80B2.3513.17 million shs9.88 million shsRXRXRecursion Pharmaceuticals$2.94-2.6%$3.32$2.77▼$7.18$1.60B122.82 million shs19.27 million shsSDGRSchrodinger$15.32-1.8%$14.88$10.94▼$23.75$1.15B1.621.28 million shs940,293 shsSMMTSummit Therapeutics$13.81+0.4%$15.43$12.55▼$30.98$10.68B-1.263.93 million shs2.84 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health-2.20%-4.53%+2.88%+14.45%-36.45%RXRXRecursion Pharmaceuticals-2.65%-17.42%-5.47%-22.22%-45.45%SDGRSchrodinger-1.79%-7.10%-1.35%+24.15%-27.91%SMMTSummit Therapeutics+0.36%-9.44%-1.85%-45.09%-51.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHIMSHims & Hers Health 2.19Hold$30.70-6.66% DownsideRXRXRecursion Pharmaceuticals 2.20Hold$8.10175.51% UpsideSDGRSchrodinger 2.33Hold$20.2532.18% UpsideSMMTSummit Therapeutics 2.44Hold$26.9795.31% UpsideCurrent Analyst Ratings BreakdownLatest SMMT, SDGR, RXRX, and HIMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2026SDGRSchrodinger Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/15/2026SMMTSummit Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral7/13/2026HIMSHims & Hers Health Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold7/9/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$36.00 ➝ $37.007/1/2026HIMSHims & Hers Health Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $40.007/1/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$25.00 ➝ $36.006/17/2026HIMSHims & Hers Health BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$29.00 ➝ $39.006/8/2026HIMSHims & Hers Health Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell6/1/2026SMMTSummit Therapeutics KeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/26/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$28.00 ➝ $25.005/22/2026HIMSHims & Hers Health UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$23.00(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHIMSHims & Hers Health$2.35B3.24$0.82 per share40.24$2.38 per share13.82RXRXRecursion Pharmaceuticals$74.68M20.86N/AN/A$2.14 per share1.37SDGRSchrodinger$255.87M4.42N/AN/A$4.94 per share3.10SMMTSummit TherapeuticsN/AN/AN/AN/A$0.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHIMSHims & Hers Health$128.37M-$0.09N/A63.2594.78-0.56%6.10%1.52%8/10/2026 (Estimated)RXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%8/4/2026 (Estimated)SDGRSchrodinger-$103.26M-$1.41N/AN/AN/A-40.61%-30.85%-15.32%8/5/2026 (Estimated)SMMTSummit Therapeutics-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%8/10/2026 (Estimated)Latest SMMT, SDGR, RXRX, and HIMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026HIMSHims & Hers Health-$0.07N/AN/AN/A$691.65 millionN/A8/10/2026Q2 2026SMMTSummit Therapeutics-$0.26N/AN/AN/A$0.11 millionN/A8/5/2026Q2 2026SDGRSchrodinger-$0.4145N/AN/AN/A$47.20 millionN/A8/4/2026Q2 2026RXRXRecursion Pharmaceuticals-$0.25N/AN/AN/A$10.97 millionN/A5/11/2026Q1 2026HIMSHims & Hers Health$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million5/5/2026Q1 2026SDGRSchrodinger-$0.56-$0.81-$0.25-$0.81$47.57 million$58.59 million5/1/2026Q1 2026SMMTSummit Therapeutics-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHIMSHims & Hers HealthN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHIMSHims & Hers Health2.181.691.56RXRXRecursion Pharmaceuticals0.015.475.47SDGRSchrodingerN/A2.742.74SMMTSummit TherapeuticsN/A7.417.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHIMSHims & Hers Health63.52%RXRXRecursion Pharmaceuticals89.06%SDGRSchrodinger79.05%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipHIMSHims & Hers Health11.76%RXRXRecursion Pharmaceuticals6.65%SDGRSchrodinger10.10%SMMTSummit Therapeutics83.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHIMSHims & Hers Health2,442231.46 million204.24 millionOptionableRXRXRecursion Pharmaceuticals400529.91 million494.67 millionOptionableSDGRSchrodinger79073.82 million66.37 millionOptionableSMMTSummit Therapeutics110776.16 million128.07 millionOptionableSMMT, SDGR, RXRX, and HIMS HeadlinesRecent News About These CompaniesSummit Therapeutics (NASDAQ:SMMT) Downgraded by Wall Street Zen to "Sell"July 18 at 1:35 AM | marketbeat.comKuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law FirmJuly 17 at 4:01 PM | globenewswire.comSummit Therapeutics (NASDAQ:SMMT) Share Price Crosses Below 50-Day Moving Average - What's Next?July 17 at 3:39 AM | marketbeat.comSummit to Divest Late-Stage Antibiotic Drug to Biossil in $105M DealJuly 15 at 9:51 AM | zacks.com119,655 Shares in Summit Therapeutics PLC $SMMT Bought by Y Intercept Hong Kong LtdJuly 9, 2026 | marketbeat.comSummit Therapeutics PLC (NASDAQ:SMMT) Given Average Rating of "Hold" by BrokeragesJuly 9, 2026 | marketbeat.comSMMT Stock Price PredictionJuly 4, 2026 | 247wallst.comHsbc Holdings PLC Buys New Shares in Summit Therapeutics PLC $SMMTJuly 1, 2026 | marketbeat.comSummit Therapeutics: High-Volatility, Catalyst-Driven Binary BetJune 22, 2026 | seekingalpha.comSummit Therapeutics PLC $SMMT Shares Bought by Baker BROS. Advisors LPJune 18, 2026 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Mahkam Zanganeh Purchases 3,810,000 SharesJune 13, 2026 | insidertrades.comWhy is SMMT stock tumbling today?June 10, 2026 | msn.comSummit Therapeutics Announces Proposed Public Offering of Common StockJune 9, 2026 | businesswire.comSummit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comMizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform TechJune 7, 2026 | 247wallst.comThe Era of the One-Size-Fits-All Cancer Drug Is EndingJune 6, 2026 | wsj.comSummit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial DataJune 5, 2026 | finance.yahoo.comSummit Therapeutics (NASDAQ:SMMT) CFO Manmeet Singh Soni Buys 50,000 SharesJune 5, 2026 | insidertrades.comSummit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare ConferenceJune 4, 2026 | businesswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT)June 4, 2026 | theglobeandmail.comAssessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return ProfileJune 4, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026SK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026Micron’s Sudden Plunge May Be an AI Buying ChanceBy Jeffrey Neal Johnson | June 23, 2026As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the WinnerBy Jessica Mitacek | July 6, 2026SMMT, SDGR, RXRX, and HIMS Company DescriptionsHims & Hers Health NYSE:HIMS$32.89 -0.79 (-2.35%) Closing price 07/17/2026 03:59 PM EasternExtended Trading$32.77 -0.12 (-0.37%) As of 07/17/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Recursion Pharmaceuticals NASDAQ:RXRX$2.94 -0.08 (-2.65%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$2.94 +0.00 (+0.17%) As of 07/17/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Schrodinger NASDAQ:SDGR$15.32 -0.28 (-1.79%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$15.30 -0.02 (-0.10%) As of 07/17/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Summit Therapeutics NASDAQ:SMMT$13.81 +0.05 (+0.36%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$13.92 +0.11 (+0.83%) As of 07/17/2026 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/13- 07/17 The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth Why Intuitive Surgical’s Strong Quarter Still Spooked Investors Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
